Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00946
|
|||||
| Drug Name |
Melagatran
|
|||||
| Synonyms |
159776-70-2; 2A9QP32MD4; C22H31N5O4; CHEBI:43966; H-319/68; MEL; MELAGATRAN (ASTRA-ZENECA); Melagatran; Melagatran (INN); Melagatran [INN]; N-((R)-(((2S)-2-((-p-Amidobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; N-((R)-(((2S)-2-((p-Amidinobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; UNII-2A9QP32MD4; [((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Atrial fibrillation [ICD11: BC81.3] | Withdrawn | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H31N5O4
|
|||||
| Canonical SMILES |
C1CCC(CC1)C(C(=O)N2CCC2C(=O)NCC3=CC=C(C=C3)C(=N)N)NCC(=O)O
|
|||||
| InChI |
InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
|
|||||
| InChIKey |
DKWNMCUOEDMMIN-PKOBYXMFSA-N
|
|||||
| CAS Number |
CAS 159776-70-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 429.5 | Topological Polar Surface Area | 149 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
-1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:43966
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (2A9QP32MD4) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.